Curated News
By: NewsRamp Editorial Staff
May 14, 2025
Glucotrack's Breakthrough in Diabetes Management: First-In-Human Study Success Fuels Ongoing Long-Term Trial
TLDR
- Glucotrack Inc. (NASDAQ: GCTK) introduces the Continuous Blood Glucose Monitor (CBGM), offering a radical departure from traditional diabetes management.
- Glucotrack's CBGM measures blood glucose directly, providing real-time readings with a fully implantable and discreet system designed for long-term use.
- Glucotrack's CBGM aims to improve the lives of insulin-dependent diabetes patients by enhancing glucose control, reducing complications, and offering a potentially game-changing solution.
- Glucotrack's First-in-Human study on the CBGM system demonstrates safety, technical feasibility, and promising performance, marking a significant step towards modernizing diabetes management.
Impact - Why it Matters
This news highlights a significant advancement in diabetes care, offering hope for improved glucose monitoring for patients with insulin-dependent diabetes. The successful first-in-human study marks a crucial step towards bringing a potentially game-changing solution to market. The upcoming OUS clinical trial will further validate the CBGM system's durability, usability, and accuracy, potentially transforming how diabetes is managed in the future.
Summary
Glucotrack Inc. is revolutionizing diabetes management with its Continuous Blood Glucose Monitor (CBGM), catering to insulin-dependent patients. The CBGM directly measures blood glucose levels, providing real-time readings and potentially more accurate results compared to traditional methodologies. A recent first-in-human study conducted in Brazil demonstrated the safety and technical feasibility of the CBGM system, paving the way for long-term evaluation through an Outside-the-United States (OUS) clinical trial.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Glucotrack's Breakthrough in Diabetes Management: First-In-Human Study Success Fuels Ongoing Long-Term Trial
